[go: up one dir, main page]

DE60040727D1 - Menschliche papillomavirus impfstoff-formulierungen - Google Patents

Menschliche papillomavirus impfstoff-formulierungen

Info

Publication number
DE60040727D1
DE60040727D1 DE60040727T DE60040727T DE60040727D1 DE 60040727 D1 DE60040727 D1 DE 60040727D1 DE 60040727 T DE60040727 T DE 60040727T DE 60040727 T DE60040727 T DE 60040727T DE 60040727 D1 DE60040727 D1 DE 60040727D1
Authority
DE
Germany
Prior art keywords
papilloma virus
virus vaccine
human papilloma
vaccine formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60040727T
Other languages
English (en)
Inventor
David B Volkin
Li Shi
Henryk Mach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60040727D1 publication Critical patent/DE60040727D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE60040727T 1999-02-05 2000-02-01 Menschliche papillomavirus impfstoff-formulierungen Expired - Lifetime DE60040727D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11872399P 1999-02-05 1999-02-05
PCT/US2000/002463 WO2000045841A2 (en) 1999-02-05 2000-02-01 Human papilloma virus vaccine formulations

Publications (1)

Publication Number Publication Date
DE60040727D1 true DE60040727D1 (de) 2008-12-18

Family

ID=22380362

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60040727T Expired - Lifetime DE60040727D1 (de) 1999-02-05 2000-02-01 Menschliche papillomavirus impfstoff-formulierungen

Country Status (15)

Country Link
US (1) US6251678B1 (de)
EP (1) EP1150712B1 (de)
JP (2) JP4841726B2 (de)
KR (1) KR20010093290A (de)
AR (1) AR022510A1 (de)
AT (1) ATE413188T1 (de)
AU (1) AU764138B2 (de)
CA (1) CA2361837C (de)
CY (1) CY1108702T1 (de)
DE (1) DE60040727D1 (de)
DK (1) DK1150712T3 (de)
ES (1) ES2313881T3 (de)
PT (1) PT1150712E (de)
SI (1) SI1150712T1 (de)
WO (1) WO2000045841A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA982950B (en) * 1997-04-08 1998-10-19 Merck & Co Inc Stabilized human papillomavirus formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CA2399321C (en) * 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
CA2327950A1 (en) * 2000-12-08 2002-06-08 Groupe Minutia Inc. Grain refining agent for cast aluminum or magnesium products
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US20030232018A1 (en) * 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
MXPA05006764A (es) * 2002-12-20 2005-09-08 Glaxosmithkline Biolog Sa Vacuna vlp l1 del vph-16 y -18.
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
JP2007001865A (ja) * 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
US7608278B2 (en) 2003-12-30 2009-10-27 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2588274A1 (en) * 2004-10-05 2006-04-13 Cytos Biotechnology Ag Vlp-antigen conjugates and their uses as vaccines
JP2008515851A (ja) * 2004-10-05 2008-05-15 サイトス バイオテクノロジー アーゲー Ｖｌｐ−抗原コンジュゲートとワクチンとしてのその使用
JP4182074B2 (ja) * 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
JP2008531722A (ja) 2005-03-04 2008-08-14 ダイナバックス テクノロジーズ コーポレイション 構造的に安定なコンジュゲート分子を含む組成物
EP1877087B1 (de) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
EP2641613A1 (de) 2006-09-29 2013-09-25 Ligocyte Pharmaceuticals, Inc. Flüssige Norovirus-Impfstoff-Formulierungen enthaltend "toll-like" Rezeptor (TLR) Agonisten als Adjuvans
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
US9439958B2 (en) * 2009-12-23 2016-09-13 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Stabilized virus like particles having enhanced mucosal immunogenicity
PT2608805T (pt) 2010-08-23 2017-09-11 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
EP2723371B1 (de) * 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv-impfstoffformulierungen mit einem aluminiumadjuvans sowie herstellungsverfahren dafür
MX379496B (es) 2011-07-11 2025-03-11 Takeda Vaccines Inc Formulaciones parenterales de vacunas contra los norovirus.
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
ES2765880T3 (es) 2012-01-09 2020-06-11 Sanofi Pasteur Biologics Llc Purificación del virus del herpes
JP5925342B2 (ja) 2012-03-09 2016-05-25 ファイザー・インク 髄膜炎菌（Ｎｅｉｓｓｅｒｉａｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
CN104379170B (zh) 2012-06-20 2017-05-03 国立大学法人东京大学 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物
JOP20130186B1 (ar) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
DK3421997T3 (da) * 2012-12-28 2020-09-14 Cellestis Ltd Cellemedieret immunresponsanalyse
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN106461667A (zh) 2014-01-31 2017-02-22 乌利塞生物医药公司 用于检测感染及相关病症的生物传感器
CN104479892A (zh) * 2014-11-06 2015-04-01 王越 一种具有植物杀菌功能洗衣液的制备方法
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP4483903A3 (de) * 2016-04-01 2025-04-02 Colorado State University Research Foundation Zusammensetzungen und verfahren für verbesserte angeborene immunität
US12508279B2 (en) 2016-04-01 2025-12-30 Colorado State University Research Foundation Compositions and methods for enhancing innate immunity in a subject for treatment of infections and cancer and other acute and chronic conditions of the eye
IL303108B2 (en) 2017-01-31 2024-07-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
BR112020008482A8 (pt) * 2017-11-01 2023-01-31 Merck Sharp & Dohme Composto leuco
CN112439059B (zh) * 2019-09-02 2022-02-08 怡道生物科技(苏州)有限公司 重组人乳头瘤病毒疫苗组合物及其用途
EP4034157A1 (de) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria-meningitidis-zusammensetzungen und verfahren dafür
JP2026000483A (ja) * 2022-11-22 2026-01-06 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン
WO2025216920A1 (en) * 2024-04-08 2025-10-16 The Government Of The United States, As Represented By The Secretary Of The Army Freezable aqueous aluminum salt adjuvants

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
PT757717E (pt) * 1994-05-16 2006-09-29 Merck & Co Inc Vacinas de papilomavirus
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ATE377428T1 (de) * 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
AU739829B2 (en) * 1997-04-08 2001-10-18 Merck Sharp & Dohme Corp. Stabilized human papillomavirus formulations

Also Published As

Publication number Publication date
WO2000045841A3 (en) 2000-12-14
JP2002536340A (ja) 2002-10-29
PT1150712E (pt) 2008-12-22
EP1150712A2 (de) 2001-11-07
SI1150712T1 (sl) 2009-02-28
CY1108702T1 (el) 2013-09-04
US6251678B1 (en) 2001-06-26
ES2313881T3 (es) 2009-03-16
JP2011225578A (ja) 2011-11-10
AU2749200A (en) 2000-08-25
KR20010093290A (ko) 2001-10-27
CA2361837C (en) 2011-06-07
AU764138B2 (en) 2003-08-14
WO2000045841A2 (en) 2000-08-10
DK1150712T3 (da) 2009-02-02
EP1150712B1 (de) 2008-11-05
ATE413188T1 (de) 2008-11-15
JP4841726B2 (ja) 2011-12-21
AR022510A1 (es) 2002-09-04
CA2361837A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
DE60040727D1 (de) Menschliche papillomavirus impfstoff-formulierungen
LU91326I2 (fr) Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
DE60024893D1 (de) Impfstoff gegen HPV
HUP0301308A3 (en) Human papilloma virus treatment
NO20014322D0 (no) Vaksine
ATE490327T1 (de) Impfstoffzusammensetzung
NO20030713L (no) Oral faststoffdose vaksine
PT1210112E (pt) Vacina contra hbv e hpv
FR16C0014I2 (fr) Vaccin contre le virus de la fievre du nil
DZ3219A1 (fr) Vaccin
DE60002650D1 (de) Öladjuvierter Impfstoff
HUP0202770A3 (en) Human papilloma virus vaccine
EP1389043A4 (de) Impfstoff gegen das maul- und -klauensäure-virus
IS6184A (is) Bóluefni gegn ISA veiru
GB9911823D0 (en) New vaccine formulations
AU6268199A (en) Live virus vaccines to protect primates from hiv-1 infection and disease
ITMI992410A0 (it) Vaccino per hiv
SI1296711T1 (sl) HPV-E7 za zdravljenje humanih papilomavirusnih infekcij
GB9911824D0 (en) New vaccine formulations
GB9911825D0 (en) New vaccine formulations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1150712

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1150712

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213